Amneal Pharmaceuticals' Q2 revenue misses estimates

Amneal Pharmaceuticals

05/08/2025 11:20

Repeats to attach to corrected alerts

Overview

Amneal Q2 2025 net revenue rises 3% but misses analyst expectations, per LSEG data

Adjusted EBITDA for Q2 2025 increases 13% to $184 mln, reflecting higher revenue and gross margin

Co raises full year 2025 guidance, citing strong product uptake and FDA approval

Outlook

Amneal raises 2025 adjusted EBITDA guidance to $665 mln - $685 mln

Company increases 2025 adjusted EPS forecast to $0.70 - $0.75

Amneal boosts 2025 operating cash flow outlook to $275 mln - $305 mln

Company expects 2025 net revenue between $3.0 bln and $3.1 bln

Result Drivers

SPECIALTY SEGMENT - Specialty net revenue rose 23% due to strong performance of branded products like CREXONT and RYTARY

DEBT REFINANCING - Successful debt refinancing reduced interest costs and extended maturities, improving financial position

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$724.51 mln
$744.60 mln (4 Analysts)
Q2 Net Income
$35.61 mln
Q2 Gross Profit
$286.25 mln
Q2 Operating Income
$111.37 mln
Q2 Pretax Profit
$51.71 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Amneal Pharmaceuticals Inc is $12.00, about 33.7% above its August 4 closing price of $7.96

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nGNX7xhvwb

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)